Brief: Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024
17/12/2024 21:48
Dec 17 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O :
* CORVUS PHARMACEUTICALS TO ANNOUNCE INTERIM DATA FROM
PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR
ATOPIC DERMATITIS ON DECEMBER 18, 2024
Source text: ID:nGNXqLLNv
Further company coverage: CRVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental